Investigation of imatinib and other approved drugs as starting points for antidiabetic drug discovery with FXR modulating activity.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Biochemical Pharmacology

• Publication date

  2012-06-15

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bcp.2012.02.027PMID 22414727
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lowering Bile Acid Pool Size with a Synthetic Farnesoid X Receptor (FXR) Agonist Induces Obesity and Diabetes through Reduced Energy Expenditure*

  2011cited by this paper
• Pharmacophore-based discovery of FXR agonists. Part I: Model development and experimental validation

  2011cited by this paper
• Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.

  2011cited by this paper
• Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing?

  2011cited by this paper
• ChEMBL: a large-scale bioactivity database for drug discovery

  2011cited by this paper
• Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice

  2011cited by this paper
• Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes.

  2010cited by this paper
• Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.

  2010cited by this paper
• Target Profile Prediction: Cross‐Activation of Peroxisome Proliferator‐Activated Receptor (PPAR) and Farnesoid X Receptor (FXR)

  2010cited by this paper
• Antidiabetic sulfonylureas modulate farnesoid X receptor activation and target gene transcription.

  2010cited by this paper
• Anti-atherogenic effects of montelukast associated with reduced MCP-1 expression in a rabbit carotid balloon injury model.

  2009cited by this paper
• Improvement of hepatic fibrosis by leukotriene inhibition in cholestatic rats.

  2009cited by this paper
• Imatinib Mesylate Reduces Endoplasmic Reticulum Stress and Induces Remission of Diabetes in db/db Mice

  2009cited by this paper
• Potential of Small Molecule Protein Tyrosine Kinase Inhibitors as Immunomodulators and Inhibitors of the Development of Diabetes

  2009cited by this paper
• Self-organizing maps in drug discovery: compound library design, scaffold-hopping, repurposing.

  2009cited by this paper
• Restoration of insulin sensitivity following treatment with imatinib mesylate (Gleevec) in non-diabetic patients with chronic myelogenic leukemia (CML).

  2008cited by this paper
• Imatinib mesylate improves insulin sensitivity and glucose disposal rates in rats fed a high-fat diet.

  2008cited by this paper
• Identification of a potent synthetic FXR agonist with an unexpected mode of binding and activation

  2008cited by this paper
• Targeting farnesoid X receptor for liver and metabolic disorders.

  2007cited by this paper
• DrugBank: a knowledgebase for drugs, drug actions and drug targets

  2007cited by this paper
• Functional characterization of vitamin D responding regions in the human 5-Lipoxygenase gene.

  2007cited by this paper
• Halofenate Is a Selective Peroxisome Proliferator–Activated Receptor γ Modulator With Antidiabetic Activity

  2006cited by this paper
• Selective optimization of side activities: the SOSA approach.

  2006cited by this paper
• Scaffold‐Hopping Potential of Ligand‐Based Similarity Concepts

  2006cited by this paper
• The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism.

  2005cited by this paper
• Insight into hepatotoxicity: The troglitazone experience

  2005cited by this paper
• Imatinib and regression of type 2 diabetes.

  2005cited by this paper
• Self-organized formation of topologically correct feature maps

  2004cited by this paper
• Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment.

  2004cited by this paper
• Imatinib Attenuates Diabetes-Associated Atherosclerosis

  2004cited by this paper
• A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR.

  2003cited by this paper
• Effects of phosphodiesterase 3,4,5 inhibitors on hepatocyte cAMP levels, glycogenolysis, gluconeogenesis and suceptibility to a mitochondrial toxin

  2003cited by this paper
• Combating diabetes.

  2002cited by this paper
• New Weapons to Combat an Ancient Disease: Treating Diabetes

  2002cited by this paper
• The Nobel chronicles. 1998: Robert Francis Furchgott (b 1911), Louis J Ignarro (b 1941), and Ferid Murad (b 1936).

  2000cited by this paper
• Estrogen receptor transcription and transactivation: Estrogen receptor alpha and estrogen receptor beta - regulation by selective estrogen receptor modulators and importance in breast cancer

  2000cited by this paper
• "Scaffold-Hopping" by Topological Pharmacophore Search: A Contribution to Virtual Screening.

  1999cited by this paper
• Endogenous bile acids are ligands for the nuclear receptor FXR/BAR.

  1999cited by this paper
• Concepts and applications of molecular similarity

  1990cited by this paper
• Self-organized formation of topographically correct feature maps

  1982cited by this paper

• COVID-19 and Diarylamidines: The Parasitic Connection

  2023cites this paper
• Farnesoid X receptor regulators from natural products and their biological function.

  2023cites this paper
• How fullerene derivatives (FDs) act on therapeutically important targets associated with diabetic diseases

  2022cites this paper
• Natural Products Targeting Liver X Receptors or Farnesoid X Receptor

  2022cites this paper
• Differential Therapeutic Effects of FXR Activation, sEH Inhibition, and Dual FXR/sEH Modulation in NASH in Diet-Induced Obese Mice.

  2021cites this paper
• Second-Generation Dual FXR/sEH Modulators with Optimized Pharmacokinetics.

  2021cites this paper
• Development and in vitro Profiling of Dual FXR/LTA4H Modulators

  2021cites this paper
• Recent Advances in In-Vitro Assays for Type 2 Diabetes Mellitus: An Overview

  2020cites this paper
• Ligand- and Structure-Based Drug Design and Optimization using KNIME.

  2020cites this paper
• A triple farnesoid X receptor and peroxisome proliferator-activated receptor α/δ activator reverses hepatic fibrosis in diet-induced NASH in mice

  2020cites this paper
• Molecular tuning of farnesoid X receptor partial agonism

  2019cites this paper
• Dual Farnesoid X Receptor/Soluble Epoxide Hydrolase Modulators Derived from Zafirlukast

  2019cites this paper
• Structural optimization and in vitro profiling of N-phenylbenzamide-based farnesoid X receptor antagonists.

  2018cites this paper
• Allosteric modulation of the farnesoid X receptor by a small molecule

  2018cites this paper
• Selective Optimization of Pranlukast to Farnesoid X Receptor Modulators

  2018cites this paper
• Natural products as modulators of the nuclear receptors and metabolic sensors LXR, FXR and RXR.

  2018cites this paper
• Quantitative proteomic study of the plasma reveals acute phase response and LXR/RXR and FXR/RXR activation in the chronic unpredictable mild stress mouse model of depression

  2017cites this paper
• A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis.

  2017cites this paper
• SAR studies on FXR modulators led to the discovery of the first combined FXR antagonistic/TGR5 agonistic compound.

  2016cites this paper
• The Importance of Bioactivation in Computer-Guided Drug Repositioning. Why the Parent Drug is Not Always Enough.

  2016cites this paper
• Fragmentation of GW4064 led to a highly potent partial farnesoid X receptor agonist with improved drug-like properties.

  2015cites this paper
• Anthranilic acid derivatives as nuclear receptor modulators--development of novel PPAR selective and dual PPAR/FXR ligands.

  2015cites this paper
• Design, Synthesis, and Characterization of a Photoactivatable Caged Prodrug of Imatinib

  2015cites this paper
• NSAIDs Ibuprofen, Indometacin, and Diclofenac do not interact with Farnesoid X Receptor

  2015cites this paper
• In silico polypharmacology: retrospective recognition vs. rational design

  2014cites this paper
• Anthranilic acid derivatives as novel ligands for farnesoid X receptor (FXR).

  2014cites this paper
• Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators: development of a highly potent partial farnesoid X receptor agonist.

  2014cites this paper
• Some non-conventional biomolecular targets for diamidines. A short survey.

  2014cites this paper
• Identification of novel farnesoid X receptor modulators using a combined ligand- and structure-based virtual screening

  2013cites this paper
• Positive regulation of osteogenesis by bile acid through FXR

  2013cites this paper
• Chemically Advanced Template Search (CATS) for Scaffold-Hopping and Prospective Target Prediction for ‘Orphan’ Molecules

  2013cites this paper
• Understanding, recognizing, and managing toxicities of targeted anticancer therapies

  2013cites this paper
• Navigations of chemical space to further the understanding of polypharmacology in human nuclear receptors

  2013cites this paper
• Activation of farnesoid X receptor enhances osteoblastic differentiation

  2013cites this paper
• Drug discovery applications for KNIME: an open source data mining platform.

  2012cites this paper